ClinicalTrials.gg
RecruitingNCT07193394H3RAKLESUpdated Feb 23, 2026

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

A Phase 2 interventional study of Tucatinib (ONT-380) and Trastuzumab (Herceptin) in Metastatic Breast Cancer ( HER2 Negative) and Unresectable Breast Cancer, sponsored by Institut Curie. Recruiting at 9 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Institut Curie · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.

Planned enrollment
23rd of 31
20 · median 41
Started
2026
the only one that year
Phase 2
16 of 31
6 open now
Primary completion
2028-12
later than 16 of 18 live
Registered
31st of 31
by date
Lead sponsor
2 of 31
Institut Curie

Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 23rd largest by planned enrollment, is the only one that started in 2026, is one of 16 in phase 2, reaches primary completion later than 16 of the 18 other live ones, and was the 31st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tucatinib

tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing tucatinib in Breast Neoplasms, or all of them as a file.
02

Study summary

The H3RAKLES trial would allow patients with a progressive metastatic breast cancer to have access to one more line of systemic therapy. Patients included in this trial will have already received at least two lines of chemotherapy (and potentially several lines of endocrine therapy for patients with a HR+ disease). In this setting, few treatments have demonstrated a clinically meaningful benefit, and any additional option is valuable. Furthermore, the pre-clinical and clinical rationale indicate a high probability of clinical benefit, as previously shown in Table 1, with all patients treated with trastuzumab and a TKI targeting HER2 displaying a response. Besides, with several years of hindsight for the combination of lapatinib, trastuzumab and capecitabine, we expect excellent tolerance with the same treatment without capecitabine.

The H3RAKLES single-arm phase II trial will evaluate the combination of tucatinib, a HER2 TKI, and trastuzumab, a HER2-directed antibody in patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation. To demonstrate the actionability of ERBB3 mutations, all patients will receive a combination of trastuzumab and tucatinib, in 3-weeks cycles.

Read the detailed description

For breast cancers in which HER2 is not overexpressed, activating mutations in the ERBB3 gene, coding for the HER3 tyrosine kinase receptor, have an oncogenic role, and targeting them may offer new perspectives of treatment.

Pre-clinical data suggest that HER2 is essential for the pro-tumoral effect of HER3, which does not have a functional tyrosine kinase domain and requires heterodimerization with other members of the HER family of tyrosine kinase receptors for signaling. There is limited clinical evidence of the activity of drugs targeting HER2 in cancers harboring ERBB3 mutations, but few patients with breast cancer have been evaluated. Furthermore, the distribution of ERBB3 mutations seems to differ in breast carcinoma when compared to other cancer types. A few patients with a HER2 non-amplified metastatic breast cancer were treated at Institut Curie with the combination of a HER2-directed antibody and of a HER2 tyrosine kinase inhibitor (TKI) and all responded, warranting further explorations in this setting.

The H3RAKLES single-arm phase II trial will evaluate the combination of tucatinib, a HER2 TKI, and trastuzumab, a HER2-directed antibody, with a Bayesian design in patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation.

To demonstrate the actionability of ERBB3 mutations, all patients will receive a combination of trastuzumab and tucatinib, in 3-weeks cycles, until cancer progression, inacceptable toxicity or patient's withdrawal from the trial.

Tumor radiological assessments will be performed every 6 weeks during the 6 first months (first 8 cycles), then every 9 weeks until disease progression. In addition, Quality of Life will be evaluated throughout the treatment.

Blood samples (at baseline, cycles 1, 2 and 3, and at end of treatment) and tissue samples (at baseline and optionally at progression) will be collected as part as exploratory objective analyses on biomarkers (ctDNA monitoring and next-generation sequencing (NGS)).

03

Conditions studied

  • Metastatic Breast Cancer ( HER2 Negative)
  • Unresectable Breast Cancer

Keywords

  • Breast
  • Cancer
  • HER2
  • tucatinib
  • trastuzumab
  • HER3
  • metastatic
  • unresectable
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • or unresectable breast cancer
  • -negative (defined as having an IHC 0+, IHC 1+, or IHC 2+ and ISH non-amplified, per ASCO/CAP guidelines) on last assessable tumor sample
  • Having received ≥ 2 previous chemotherapy lines for advanced breast cancer: including at least one line of conjugated antibody, at the investigator's discretion or if a germinal BRCA mutation is present, a PARP inhibitor.
  • Class IV or V somatic ERBB3 mutation as determined on a tumor sample obtained during the molecular screening step
  • performance status ≤ 2 (Appendix A)
  • Evaluable disease, per v1.1 inclusion criteria
  • (LVEF) ≥50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study treatment
  • Adequate organ function:

    1. ≥ 50 mL/min as calculated per institutional guidelines
    2. Total ≤1.5 X (ULN), except for patients with known Gilbert's disease, who may enroll if the conjugated bilirubin is ≤1.5 X ULN.
    3. Transaminases ( and alanine aminotransferase) ≤ 2.5 X ULN (≤ 5 X ULN if the patient has liver metastases)
  • Women of (WCBP) must have a negative serum pregnancy test \< 7 days prior to first dose of treatment. A woman is considered of childbearing potential following menarche and until becoming unless permanently sterile. A postmenopausal state is defined as the absence of menses for 12 months without an alternative cause.
  • WCBP (as defined above) and men with partners of childbearing potential must agree to use a highly effective method during the study and for 3 months after completion of treatment.
  • Patients should be eligible for the treatment step according to the investigator's opinion.
  • Patients must be covered by a health insurance plan.
  • Patients able to provide signed .

Exclusion criteria

Exclusion Criteria:

  • Having received any prior treatment targeting . Prior treatment with trastuzumab deruxtecan is allowed, per label, in patients with HER2-low breast cancer (IHC 1+ or 2+, ISH non-amplified)
  • History of allergic reactions to trastuzumab or tucatinib or chemically similar drugs
  • Patients who are pregnant, breastfeeding, or planning a pregnancy from time of until 7 months after the final dose of study drug
  • Inability to swallow pills or having a significant gastro-intestinal disease or a history of surgery which would preclude the adequate oral absorption of medications
  • Having used a strong CYP2C8 inhibitor within a duration of 5 half-lives prior to the first dose of study treatment, or have used a strong or CYP2C8 inducer within 5 days prior to first dose of study treatment (see Appendix B and Appendix C)
  • Treatment with any systemic anti-cancer therapy (including hormonal therapy), non-central nervous system (CNS) radiation, or experimental agent ≤ 3 weeks prior to the first dose of study treatment, except gonadotropin releasing hormone (GnRH) agonists
  • Participation in another interventional clinical trial.
  • Symptomatic and untreated or brain metastases requiring urgent treatment, or brain metastases requiring a dose > 2 mg of dexamethasone (or equivalent)
  • Whole brain radiotherapy \< 21 days prior to first dose of treatment, stereotactic radiotherapy \< 7 days prior to first dose of treatment
  • Major surgery (including surgery of brain metastases) \< 21 days prior to first dose of treatment
  • Evidence within 2 years of the start of study treatment of another that required systemic treatment
  • Have known myocardial infarction or unstable angina within 24 weeks prior to first dose of study treatment
  • Have cardiopulmonary disease such as:

    • Ventricular arrhythmia requiring therapy,
    • Uncontrolled hypertension (defined as persistent systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mm Hg on antihypertensive medications)
    • Any history of symptomatic congestive heart failure
    • Severe dyspnea at rest ( v5.0 Grade 3 or above) due to complications of advanced malignancy
    • Hypoxia requiring supplementary oxygen therapy except when oxygen therapy is needed only for obstructive sleep apnea
    • Presence of ≥ Grade 2 prolongation on screening
  • Conditions potentially resulting in drug-induced prolongation of the QT interval or torsade de pointes:

    • Congenital or acquired long QT syndrome
    • Family history of sudden death
    • History of previous drug-induced QT prolongation
    • Current use of medications with known and accepted associated risk of QT prolongation (see row "Accepted Association" in Appendix D)
  • Are known carriers of active or or have other known chronic liver disease
  • Are known to be positive for (HIV)
  • Altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.
  • Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons
  • Person deprived of liberty or under guardianship
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment with tucatinib and trastuzumab combination

    Patients with HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation, treated with a combination of tucatinib and trastuzumab

    Drug: Tucatinib (ONT-380) · Drug: Trastuzumab (Herceptin)

Interventions

  • DrugTucatinibStudies of TucatinibTucatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination

06

What researchers measure

Primary outcomes

  1. Clinical benefit rate (CBR)

    Clinical benefit rate (CBR), defined as the proportion of patients who achieved a complete response (CR), a partial response (PR), or had stable disease (SD) for 24 weeks or more, according to the investigator-assessed RECIST v1.1 criteria.

    Time frame: 24 weeks

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS), defined as the time from inclusion to progression or death.

    Time frame: 18 months

  2. Overall survival (OS)

    Overall survival (OS), defined as the time from inclusion to death by any cause.

    Time frame: 18 months

  3. Objective response rate (ORR)

    Objective response rate, defined as the proportion of patients who achieved a CR or PR according to the investigator-assessed RECIST v1.1 criteria.

    Time frame: 18 months

  4. Safety of the trastuzumab/tucatinib combination

    Adverse Events (AEs) and Serious Adverse Events (SAEs), per CTCAE v5.0, considered by the investigator as related to trastuzumab or tucatinib.

    Time frame: 18 months

07

Study locations

1 of 9 sites recruiting
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, 33 300, France
    Not yet recruiting
    • Laura POETSCH, MD · Contact
    • Laura POETSCH, MD · Principal investigator
  • Chu Dupuytren- Limoges
    Limoges, 87 042, France
    Not yet recruiting
    • Elise DELUCHE, MD · Contact
    • Elise DELUCHE, MD · Principal investigator
  • Institut Paoli-Calmettes
    Marseille, 13009, France
    Not yet recruiting
    • Alexandre TASSIN DE NONNEVILLE, MD · Contact
    • Alexandre TASSIN DE NONNEVILLE, MD · Principal investigator
  • Centre Antoine Lacassagne
    Nice, 06 189, France
    Not yet recruiting
    • Marc PUJALTE-MARTIN, MD · Contact
    • Marc PUJALTE-MARTIN, MD · Principal investigator
  • CHU de Nîmes
    Nîmes, 30 029, France
    Not yet recruiting
    • Frédéric FITENI, MD · Contact
    • Frédéric FITENI, MD · Principal investigator
  • Centre Eugène Marquis
    Rennes, 35 042, France
    Not yet recruiting
    • Antoine DELEUZE, MD · Contact
    • Antoine DELEUZE, MD · Principal investigator
  • Institut Curie_ Site Saint-Cloud
    Saint-Cloud, 92 210, France
    Recruiting
    • Nicolas KIAVUE, MD · Contact
    • Nicolas KIAVUE, MD · Principal investigator
  • Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud
    Toulouse, 31 059, France
    Not yet recruiting
    • Florence DALENC, MD · Contact
    • Florence DALENC, MD · Principal investigator
  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, 54 519, France
    Not yet recruiting
    • Vincent MASSARD, MD · Contact
    • Vincent MASSARD, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies. IPD sharing Supporting Information: cases à cocher Study Protocol, Statistical Analysis Plan (SAP).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2028, 34 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 34 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 25, 2025
StartEst.
Jan 31, 2026
Primary completionEst.
Dec 7, 2028
CompletionEst.
Jun 8, 2029
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193394
Lead sponsor
Institut Curie
Collaborators
Pfizer, Eurofins, UNICANCER
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Jan 31, 2026 (estimated)
Primary completion
Dec 7, 2028 (estimated)
Completion
Jun 8, 2029 (estimated)
Last update
Feb 23, 2026

Study contacts

Sandra Clinical Project Manager
Contact
drci.promotion@curie.fr
+33156245944
Sandra Regulatory Assistant
Contact
drci.promotion@curie.fr
+33156245765
François-Clément Bidard, Prof.
principal investigator · Institut Curie
Sandra BIDARD
principal investigator · Institut Curie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucatinib · Trastuzumab

Start the discussion